These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2544429)

  • 1. Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.
    Harding M; Docherty V; Mackie R; Dorward A; Kaye S
    Eur J Cancer Clin Oncol; 1989 May; 25(5):785-8. PubMed ID: 2544429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
    Gundersen S; Aamdal S; Fodstad O
    Br J Cancer; 1987 Apr; 55(4):433-5. PubMed ID: 3580266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.
    Neijt JP; van der Burg ME; Guastalla JP; George M; Piccart M; Vermorken J; Carnino F; Rotmensz N
    Acta Oncol; 1989; 28(5):663-5. PubMed ID: 2590542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of mitozolomide in ovarian cancer.
    Harding M; Northcott D; Smyth J; Stuart NS; Green JA; Newlands E
    Br J Cancer; 1988 Jan; 57(1):113-4. PubMed ID: 3348943
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.
    Herait P; Armand JP; Benahmed M; Domenge C; Fontana X; Recondo G; Cvitkovic E; Delgado FM
    Med Oncol Tumor Pharmacother; 1989; 6(4):267-9. PubMed ID: 2615530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of mitozolomide on a once daily for 5 days schedule.
    Schornagel JH; Simonetti G; Dubbelman R; ten Bokkel Huinink WW; McVie JG
    Cancer Chemother Pharmacol; 1990; 26(3):237-8. PubMed ID: 2357772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
    Smyth JF; Gundersen S; Renard J; Pinedo HM
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):755-7. PubMed ID: 2714350
    [No Abstract]   [Full Text] [Related]  

  • 10. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
    Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.
    Herait P; Rougier P; Oliveira J; Delgado FM; May-Levin F; Hayat M; Armand JP
    Invest New Drugs; 1988 Dec; 6(4):323-5. PubMed ID: 3229944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Stoter G; Bono AV; Splinter TA; Fossa SD; Verbaeys AJ; de Mulder PH; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1249-50. PubMed ID: 2767112
    [No Abstract]   [Full Text] [Related]  

  • 13. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
    Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
    Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
    Dercksen MW; Hoekman K; ten Bokkel Huinink WW; Rankin EM; Dubbelman R; van Tinteren H; Wagstaff J; Pinedo HM
    Br J Cancer; 1993 Nov; 68(5):996-1003. PubMed ID: 7692922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study].
    Reck M; Haering B; Koschel G; Kaukel E; von Pawel J; Gatzemeier U
    Pneumologie; 1998 Oct; 52(10):570-3. PubMed ID: 9847635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
    Coudert B; Anthoney A; Fiedler W; Droz JP; Dieras V; Borner M; Smyth JF; Morant R; de Vries MJ; Roelvink M; Fumoleau P;
    Eur J Cancer; 2001 Nov; 37(17):2194-8. PubMed ID: 11677106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
    Fodstad O; Aamdal S; Pihl A; Boyd MR
    Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
    Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
    J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
    Kjønniksen I; Breistøl K; Fodstad O
    Cancer Res; 1992 Mar; 52(5):1347-51. PubMed ID: 1737396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
    Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U
    Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.